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taken from the essential drug list and the database of drugs prices. Standard 
of treatment of CP developed by Ministry of Health of the Russian Federation 
was used for calculation of medical care costs. Costs of adverse events were 
calculated basing on Russian clinical guidelines and database of drugs prices. 
Disability pensions and disable child care were taken from the Russian Pension 
Fund database. The cost of orthopedic surgeries was calculated on the basis of RF 
Government program of state guarantees of free rendering to citizens of medi-
cal care. Results: Usage of AbobotulinumtoxinA treatment+standard therapy 
in whole population of SCP patients in Russia will result in 79,585 RUB/1,473 
$ economy compared with OnabotulinumtoxinA+standard therapy, 131,178 
RUB/2,429 $ economy compared with standard therapy per one patient for 2 
years. This cost reduction is mainly attributed to decrease of number of ortho-
pedic surgeries to the better efficacy of this BTA drug. ConClusions: Inclusion 
of abobotulinumtoxinA+standard therapy appears to be a cost saving treatment 
option in the management of spastic cerebral palsy in the Russian Federation com-
pared with onabotulinumtoxinA+standard therapy and standard therapy solely.
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objeCtives: PEGIFN beta-1a is the first pegylated interferon beta-1a administered 
subcutaneously every two weeks, indicated for the therapy of relapsing remit-
ting multiple sclerosis (RRMS). The objective of this analysis was to estimate the 
potential economic impact following due of the introduction of PEGIFN beta-1a in 
Italy. Methods: The analysis was conducted with a three-year time horizon with 
the support of a decision-analytic model adopting the perspective of the Italian 
National Healthcare Service (NHS). Healthcare costs sustained by the Italian NHS for 
the management of the RRMS population (drug treatment, monitoring, relapse man-
agement, adverse event management) were calculated over 3 years and compared 
for two scenarios: i) The current scenario where only interferon beta and glatiramer 
acetate are RRMS patients available and ii) An alternative scenario after the intro-
duction of PEGIFN beta-1a. The RRMS population was estimated to be approximately 
35,500, 37,500 and 39,500 patients at Year 1, 2 and 3 respectively, based on published 
epidemiology literature and market data. The efficacy of treatments was simulated 
as reduction of relapse rates and was derived from a mixed treatment comparison. 
Unit costs were based on Italian 2015 prices and tariffs, and the published literature. 
A one-way sensitivity analysis was developed. Results: According to current price 
and reimbursement conditions established by the Italian NHS, the introduction 
of PEGIFNb-1a will result in cost savings. This model found that PEGIFN beta- 1a 
would provide in related of treating RRMS patients an estimated annual costs of 
€ 318,800,000, € 336,100,000 and € 353,600,000 in Year 1, 2, and 3 respectively compared 
to the costs of the current scenario of € 319,200,000, € 337,200,00 and € 355,200,000 
in Year 1, 2, and 3, respectively. The cumulative budget reduction over the three 
year period was € 3,100,000 (an approximate 0.3% savings). ConClusions: The 
adoption of PEGIFN beta-1a for the treatment of RRMS is economically sustainable 
by the Italian NHS.
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bACkgRound: Epileptic seizures are associated with significantly impaired quality 
life, excessive healthcare resource use and thus high costs. According to published 
sources based on clinical data new anti-epileptic add-on therapy options for refrac-
tory patients with partial-onset seizures with or without secondary generalisation, 
such as lacosamide and perampanel, has achieved greater efficacy by responder 
rates (better control of the seizures) and seizure freedom than placebo being equally 
effective between each other. objeCtives: to estimate the budgetary impact of the 
introduction of 2 types of adjunctive treatment in adult patients with refractory 
partial epilepsy (RPE) - lacosamide and perampanel added to standard treatment, 
and to forecast this impact over the following three years in Kaliningrad region of 
Russian Federation. Methods: The budget impact model has been developed for 
the Russian Federation regions. Efficacy data used to assess the resource consump-
tion was taken from randomized clinical trials and meta-analysis. The demographic 
parameters and the partial epilepsy incidence were calculated based on the official 
statistic surveillance system data for the regions. Resource use was estimated by 
expert survey. Drug and other medical costs were calculated on the basis of regis-
tered vital and essential drug list prices and regional tariffs. Results: Introduction 
of lacosamide to clinical practice (as add-on anti-epileptic treatment) compared to 
perampanel with equal market shares of 10%, 20% and 30% leads to average budget 
savings of healthcare system in Kaliningrad region, which amounted to: € 27 081.25 
in first year, € 43 746.63 in the second year, € 78 119.00 in the third year, for treat-
ing 131, 140 and 149 patients with RPE, respectively. ConClusions: The analysis 
showed that introduction of adjunctive therapy with lacosamide in the market for 
the treatment of patients with PRE compared to perampanel could save budget 
funds by reducing drug costs in Russian Federation regions.
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SC IFNβ -1a is projected to avoid 28, 10, and 10 additional escalations to second-line 
therapy compared with IM IFNβ -1a, IFNβ -1b, and GA, respectively, resulting in cost sav-
ings of £685,391, £231,021, and £231,021. Results were most sensitive to each therapy’s 
risk of relapse at 2 years. ConClusions: Among newly-diagnosed RRMS patients, 
treatment with SC IFNβ -1a is projected to avoid more relapses and escalations to 
second-line therapy compared with IM IFNβ -1a, IFNβ -1b, and GA over 2 years. These 
projected cost offsets within the UK may be applicable to other payer environments.
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objeCtives: Botulinum toxins (BT) are a valuable treatment option for patients 
with post-stroke upper-limb spasticity (PS-ULS), which affects 33,000 patients in 
the UK. Xeomin (incobotulinum toxin A) and Botox (onabotulinum toxin A) are 
two BTs licensed for the treatment of PS-ULS. The treatment costs for Xeomin and 
Botox will depend on their real-world usage. Methods: Dosing data were col-
lected for patients switching from Botox to Xeomin treatment between 2007–2012 
from the Mid-Yorkshire Hospitals Trust (MYHT) UK (comprised of 3 centres). The 
dose of each BT received per limb at each visit was extracted from the dataset for 
7 visits (the 3 visits before and 4 visits after switching). List prices from the British 
National Formulary for different vial sizes were applied to these data to generate a 
simple budget impact model. Results: 89 patients (127 limbs) were identified who 
switched treatment from Botox to Xeomin, of which 49 patients (54 limbs) fulfilled 
study criteria. The average dose of Xeomin was 147.2 units per limb and Botox was 
156.9 units per limb. Due to the lower list price of Xeomin and the comparable 
dosing frequency between Botox and Xeomin (average time between injections 
was 154 days for Botox and 156 days for Xeomin), switching resulted in an aver-
age cost-saving of £26 per limb, per visit. This represented an estimated overall 
annual saving of £3,263. Accounting for sharing of vials reduced the estimated 
saving slightly (£3,166 overall). The real-world saving made by MYHT was greater 
than this as this analysis included upper-limb spasticity only, therefore a number 
of limbs did not fit study criteria and were not included in the estimated annual 
savings. ConClusions: Real-world dosing for Xeomin and Botox was comparable. 
Based on the lower list price of Xeomin, this indicated potential cost savings for 
switching from Botox to Xeomin.
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objeCtives: To compare direct medical costs for patients with relapsing-remit-
ting multiple sclerosis (RRMS) treated with subcutaneous (sc) IFNβ 1a 44mcg three 
times weekly (TIW) versus other interferon-beta (IFNβ ) therapies across endpoints 
comprising the “no evidence of disease activity” (NEDA) measure. Methods: A 
decision-analytic model was developed using comparative efficacy data sourced 
from a network meta-analysis (NMA) of IFNβ therapies: scIFNβ 1a 44mcg TIW, 
scIFNβ 1b 250mcg every other day, intramuscular (im) IFNβ 1a 30mcg once weekly, 
and pegylated (peg) IFNβ 1a 125mcg every two weeks. The number of patients experi-
encing NEDA-related endpoints (relapse, new MRI activity, or disability progression) 
for each therapy was determined using risk ratios derived from odds ratios (ORs) vs. 
placebo (pairwise analysis) or vs. other IFNβ therapies (NMA analysis). The model 
followed 1,000 patients with RRMS over 2 years. Costs were sourced from the litera-
ture. One-way sensitivity analyses (OWSAs) were performed to test the robustness 
of the results. Results: Only medical costs were assessed, thus observed cost-
offsets meant fewer patients experienced NEDA-related endpoints. For scIFNβ 1a 
44mcg vs. pegIFNβ 1a, results from the pairwise analysis projected cost-offsets of 
$893,652 (relapse) and $252,219 (MRI); results from the NMA also projected cost-
offsets of $578,174 (relapse), $15,628 (disability), and $105,667 (MRI). For scIFNβ 1a 
44mcg vs. imIFNβ 1a, results from the pairwise analysis projected cost-offsets of 
$755,737 (relapse) and $239,926 (MRI); results from the NMA also projected cost-
offsets of $525,511 (relapse), $118,716 (disability), and $110,435 (MRI). For scIFNβ 1a 
44mcg vs. scIFNβ 1b, results from the pairwise analysis projected cost-offsets of 
$84,826 (relapse) and $32,435 (disability); results from the NMA also projected a 
cost-offset of $35,948 (disability). OWSAs confirmed substantial cost-offsets for the 
comparisons examined. ConClusions: The results of this decision-analytic model 
suggests that scIFNβ 1a 44mcg provides substantial cost-offsets versus other IFNβ 
treatments across NEDA-related endpoints.
PND22
BuDget ImPact aNalysIs of BotulINum toxIN tyPe a treatmeNt for 
cereBral Palsy IN the russIaN feDeratIoN
Yagudina R, Kulikov A, Ugrekhelidze D
I.M. Sechenov First Moscow State Medical University, Moscow, Russia
objeCtives: To conduct budget impact analysis of abobotulinumtoxinA+standard 
therapy, onabotulinumtoxinA+standard therapy and standard therapy solely 
in patients with spastic cerebral palsy (SCP) in Russia for 2-year period. Total 
number of patients with spastic cerebral palsy in Russia is 55 899. Methods: 
A budget impact model was developed in Excel 2013 to simulate the costs of 
spastic cerebral palsy therapy in the Russian Federation. The following costs 
were taken into account: the costs of pharmacotherapy, inpatient and outpatient, 
sanatorium-resort care, costs of adverse events, casting, orthopedic surgeons, 
disability pensions, disable child care benefit. Costs of pharmacotherapy were 
